MX2020010091A - Trombolisis direccionada para tratamiento de trombosis microvascular. - Google Patents
Trombolisis direccionada para tratamiento de trombosis microvascular.Info
- Publication number
- MX2020010091A MX2020010091A MX2020010091A MX2020010091A MX2020010091A MX 2020010091 A MX2020010091 A MX 2020010091A MX 2020010091 A MX2020010091 A MX 2020010091A MX 2020010091 A MX2020010091 A MX 2020010091A MX 2020010091 A MX2020010091 A MX 2020010091A
- Authority
- MX
- Mexico
- Prior art keywords
- fusion proteins
- treatment
- vwf
- platelet
- diseases
- Prior art date
Links
- 208000007536 Thrombosis Diseases 0.000 title abstract 2
- 230000002537 thrombolytic effect Effects 0.000 title 1
- 102000037865 fusion proteins Human genes 0.000 abstract 6
- 108020001507 fusion proteins Proteins 0.000 abstract 6
- 102000001938 Plasminogen Activators Human genes 0.000 abstract 2
- 108010001014 Plasminogen Activators Proteins 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 238000001415 gene therapy Methods 0.000 abstract 2
- 229940127126 plasminogen activator Drugs 0.000 abstract 2
- 239000013598 vector Substances 0.000 abstract 2
- 108091005804 Peptidases Proteins 0.000 abstract 1
- 239000004365 Protease Substances 0.000 abstract 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 abstract 1
- 201000007023 Thrombotic Thrombocytopenic Purpura Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000010348 incorporation Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1777—Integrin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/49—Urokinase; Tissue plasminogen activator
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Abstract
La presente invención proporciona proteínas de fusión para el suministro orientado de activadores de plasminógeno a complejos de plaquetas-VWF, o alternativamente al sitio donde estas se sitúan, de una manera independiente de fibrina. La proteína de fusión de la invención es para el uso en los métodos para la prevención o tratamiento de enfermedades o afecciones asociadas con los complejos de plaquetas-VWF, que pueden provocar trombosis microvascular en las enfermedades tal como por ejemplo púrpura trombocitopénica trombótica. Los agentes de direccionamiento preferidos para incorporación en las proteínas de fusión por ejemplo son nanocuerpos contra VWF o plaquetas. La activación del plasminógeno preferido para el uso en las proteínas de fusión comprenden los dominios de proteasa de uPA o tPA. La invención se refiere además a la molécula de ácido nucleico que codifica las proteínas de fusión de la invención, por ejemplo, un vector de terapia génica, y a composiciones farmacéuticas que comprenden las proteínas de fusión de la invención o estos vectores de terapia génica.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18164232 | 2018-03-27 | ||
| PCT/EP2019/057731 WO2019185723A1 (en) | 2018-03-27 | 2019-03-27 | Targeted thrombolysis for treatment of microvascular thrombosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020010091A true MX2020010091A (es) | 2021-01-15 |
Family
ID=61952524
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020010091A MX2020010091A (es) | 2018-03-27 | 2019-03-27 | Trombolisis direccionada para tratamiento de trombosis microvascular. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20210023187A1 (es) |
| EP (1) | EP3773665A1 (es) |
| JP (2) | JP2021519093A (es) |
| CN (1) | CN112384236A (es) |
| AU (1) | AU2019241439A1 (es) |
| CA (1) | CA3095080A1 (es) |
| MX (1) | MX2020010091A (es) |
| WO (1) | WO2019185723A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113521293B (zh) * | 2021-06-09 | 2023-03-03 | 复旦大学 | 血栓靶向的血小板递药系统及其应用 |
| CN113416724B (zh) * | 2021-06-25 | 2023-05-23 | 福州大学 | 一种组织型纤溶酶原激活剂的重组蛋白及其应用 |
| CN117229423B (zh) * | 2023-11-10 | 2024-02-06 | 北京科技大学 | 一种用于结合胶原的多肽纳米材料及其制备方法和应用 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| ATE452975T1 (de) | 1992-08-21 | 2010-01-15 | Univ Bruxelles | Immunoglobuline ohne leichte ketten |
| DK0698097T3 (da) | 1993-04-29 | 2001-10-08 | Unilever Nv | Produktion af antistoffer eller (funktionaliserede) fragmenter deraf afledt af Camelidae-immunoglobuliner med tung kæde |
| US5472692A (en) | 1993-07-02 | 1995-12-05 | New England Deaconess Hospital Corporation | Pro-urokinase mutants |
| FR2708622B1 (fr) | 1993-08-02 | 1997-04-18 | Raymond Hamers | Vecteur recombinant contenant une séquence d'un gène de lipoprotéine de structure pour l'expression de séquences de nucléotides. |
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| DK0937140T3 (da) | 1996-06-27 | 2008-01-28 | Vlaams Interuniv Inst Biotech | Antistofmolekyler, som interagerer specifikt med et målmolekyles aktive sted eller klöft |
| BR9907241A (pt) | 1998-01-26 | 2000-10-17 | Unilever Nv | Biblioteca de expressão, processo para preparar a mesma, uso de uma fonte não imunizada de sequências de ácido nucleico, e, processos para preparar fragmentos de anticorpos e, para preparar um anticorpo |
| EP1141711A1 (en) | 1999-01-05 | 2001-10-10 | Unilever Plc | Binding of antibody fragments to solid supports |
| AU2291700A (en) | 1999-01-19 | 2000-08-07 | Unilever Plc | Method for producing antibody fragments |
| EP1169453A1 (en) | 1999-04-22 | 2002-01-09 | Unilever Plc | Inhibition of viral infection using monovalent antigen-binding proteins |
| US6479280B1 (en) | 1999-09-24 | 2002-11-12 | Vlaams Interuniversitair Institutuut Voor Biotechnologie Vzw | Recombinant phages capable of entering host cells via specific interaction with an artificial receptor |
| ES2331051T3 (es) | 1999-11-29 | 2009-12-21 | Bac Ip B.V. | Inmovilizacion de moleculas de union de antigenos de un dominio. |
| EP1242460B1 (en) | 1999-11-29 | 2006-10-18 | Unilever Plc | Immobilisation of proteins using a polypeptide segment |
| DE60138333D1 (de) | 2000-03-14 | 2009-05-28 | Unilever Nv | Variabele Domänen der schweren Kette eines Antikörpers gegen menschliche Ernährungslipasen und deren Verwendungen |
| CA2380443C (en) | 2000-05-26 | 2013-03-12 | Ginette Dubuc | Single-domain antigen-binding antibody fragments derived from llama antibodies |
| EP1360207B1 (en) | 2000-12-13 | 2011-06-22 | Bac Ip B.V. | Protein arrays of camelid heavy-chain immunoglobulin variable domains |
| WO2003025020A1 (fr) | 2001-09-13 | 2003-03-27 | Institute For Antibodies Co., Ltd. | Procede pour creer une banque d'anticorps de chameaux |
| JP2005289809A (ja) | 2001-10-24 | 2005-10-20 | Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) | 突然変異重鎖抗体 |
| EP1456410A2 (en) | 2001-12-11 | 2004-09-15 | AlgoNomics N.V. | Method for displaying loops from immunoglobulin domains in different contexts |
| AU2002360068B2 (en) | 2001-12-21 | 2009-09-03 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Method for cloning of variable domain sequences |
| WO2003055527A2 (en) | 2002-01-03 | 2003-07-10 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Immunoconjugates useful for treatment of tumours |
| CN1181099C (zh) * | 2002-07-23 | 2004-12-22 | 中国人民解放军第二军医大学 | 兼抗凝溶栓双重功能的血栓靶向融合蛋白mA5UKB |
| BRPI0316092B8 (pt) | 2002-11-08 | 2021-05-25 | Ablynx Nv | anticorpos de domínio único direcionados contra o fator de necrose tumoral alfa e usos para os mesmos |
| NZ563471A (en) | 2002-11-08 | 2009-04-30 | Ablynx Nv | Camelidae antibodies against imminoglobulin E and use thereof for the treatment of allergic disorders |
| AU2004204262B2 (en) | 2003-01-10 | 2010-11-04 | Ablynx N.V. | Recombinant VHH single domain antibody from camelidae against von willebrand factor (vWF) or against collagen |
| JP2006241109A (ja) * | 2005-03-04 | 2006-09-14 | Paion Deutschland Gmbh | ヒトＰセレクチンおよびＤＳＰＡα１に対する抗体を含む融合タンパク質 |
| RU2433139C2 (ru) | 2005-05-20 | 2011-11-10 | Аблинкс Н.В. | Nanobodies tm для лечения заболеваний, опосредованных агрегацией |
| US9150903B2 (en) * | 2007-04-25 | 2015-10-06 | Translational Sciences Inc. | Method of increasing plasmin activity through antiplasmin conversion |
| EP3395372B1 (en) | 2009-02-20 | 2022-04-06 | EnhanX Biopharm Inc. | Glutathione-based drug delivery system |
| US20120321640A1 (en) * | 2009-12-01 | 2012-12-20 | Ablynx N.V. | Von willebrand factor specific binding agents and uses thereof |
| WO2018053427A1 (en) * | 2016-09-16 | 2018-03-22 | Duke University | Von willebrand factor (vwf)-targeting agents and methods of using the same |
-
2019
- 2019-03-27 AU AU2019241439A patent/AU2019241439A1/en active Pending
- 2019-03-27 US US17/041,459 patent/US20210023187A1/en active Pending
- 2019-03-27 CN CN201980035427.6A patent/CN112384236A/zh active Pending
- 2019-03-27 MX MX2020010091A patent/MX2020010091A/es unknown
- 2019-03-27 EP EP19713471.1A patent/EP3773665A1/en active Pending
- 2019-03-27 CA CA3095080A patent/CA3095080A1/en active Pending
- 2019-03-27 WO PCT/EP2019/057731 patent/WO2019185723A1/en unknown
- 2019-03-27 JP JP2020551995A patent/JP2021519093A/ja active Pending
-
2023
- 2023-11-20 JP JP2023196487A patent/JP2024028711A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20210023187A1 (en) | 2021-01-28 |
| EP3773665A1 (en) | 2021-02-17 |
| AU2019241439A1 (en) | 2020-10-22 |
| CA3095080A1 (en) | 2019-10-03 |
| JP2021519093A (ja) | 2021-08-10 |
| JP2024028711A (ja) | 2024-03-05 |
| CN112384236A (zh) | 2021-02-19 |
| WO2019185723A1 (en) | 2019-10-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020010091A (es) | Trombolisis direccionada para tratamiento de trombosis microvascular. | |
| PH12018502361A1 (en) | Gdf15 fusion proteins and uses thereof | |
| MX2018010824A (es) | Proteinas de union inducibles y metodos de uso. | |
| MX2022004786A (es) | Variante de aav2 con aflibercept para usarse en el tratamiento de una condicion o enfermedad ocular. | |
| MX2021015753A (es) | Constructo de arn. | |
| SA518400424B1 (ar) | جزيئات الجسم المضاد لعلاج السرطان | |
| PH12018500927A1 (en) | Liver-specific constructs, factor viii expression cassettes and methods of use thereof | |
| PH12019500596A1 (en) | Recombinant binding proteins and their use | |
| UA112985C2 (uk) | Одноланцюговий поліпептидний гібридний білок | |
| MX2019003716A (es) | Formulaciones farmaceuticas de anticuerpos tnf-alfa. | |
| MX2019008803A (es) | Anticuerpos contra el inhibidor del activador de plasminogeno tipo 1 (pai-1) y usos de los mismos. | |
| WO2014055836A3 (en) | Serine protease molecules and therapies | |
| MX2023001877A (es) | Meganucleasas dise?adas especificas para secuencias de reconocimiento en el gen pcsk9. | |
| IN2014DN05670A (es) | ||
| EA201991409A3 (ru) | Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения | |
| PE20191786A1 (es) | Anticuerpo monoclonal para pd-l1 | |
| MX2021006253A (es) | Terapias génicas para enfermedad neurodegenerativa. | |
| MX2019005979A (es) | Peptidos modificados. | |
| MX2021002041A (es) | Terapia génica para el tratamiento de galactosemia. | |
| MX2022004345A (es) | Construcciones de igf2 variantes. | |
| MX2019014697A (es) | Proteínas del receptor para productos finales de la glicación avanzada (rage) para el tratamiento de fibrosis y enfermedades mediadas por daño al adn. | |
| SE1750774A1 (en) | Novel nucleic acid molecules and their use in therapy | |
| ZA202110285B (en) | Antibodies and methods of use | |
| JOP20210067A1 (ar) | ناقلات العلاج الجيني kir 7.1 وطرق استخدامها | |
| MX2020009507A (es) | Anticuerpos de dominio individual que se unen a la neurotoxina del tetanos. |